240 likes | 442 Views
AM REPORT. The Budd Chiari Syndrome and Polycythemia Vera. Ryan Sanford 12.8.2009. Budd Chiari [BC], Why a Syndrome?. Any process that interrupts blood outflow from the liver : hepatic venous outflow obstruction Usually refers to obstruction in large hepatic veins or IVC NOT
E N D
The Budd Chiari Syndrome and Polycythemia Vera Ryan Sanford 12.8.2009
Budd Chiari [BC], Why a Syndrome? • Any process that interrupts blood outflow from the liver: hepatic venous outflow obstruction • Usually refers to obstruction in large hepatic veins or IVC • NOT • right heart failure • pericardial disease • sinusoidal obstructive syndome [hepatic veno-occlusive disease] • SOS is fibrotic, not thrombotic • related to hematologic transplantation • Categories: based on rapidity of onset and collateralization • Acute +/- fulminant: 20%, F>M, Severe RUQ pain, HSM, Rapid development of jaundice, ascites; AST/ALT > 5x ULN; ↑↑ bili; +/- encephalopathy • Sub-acute: 40%; variable presentation; typical is partial occlusion; asymptomatic to mildly symptomatic • Chronic: 40%; seen as cirrhosis
Signs and Symptoms • Abdominal Pain • Hepatomegaly • Ascites • N/V • Jaundice, esp if acute • Venous collateralization – varices, abdominal/flank collaterals • LEE • Absence of hepatojugular reflux • Laboratory evidence of liver dysfunction
So then, what are the causes? • FIRST THINK • Hypercoagulable • Polycythemia vera • Other myeloproliferative diseases • Multiple causes in one person often see + JAK2 mutation
Normal R hepatic vein Normal liver Centrilobular necrosis, dilated sinusoids filled with RBCs No R hepatic v. Rich collaterals ‘Spiders web’
How to diagose? • Clinical context + imaging • Liver U/s + doppler: first choice • CT Abdomen • Can see necrosis • Venous anatomy • Sequelae of liver disease • MRA Abdomen: as for CT; can help distinguish acuity • Idiopathic? Check for JAK2 mutation for myeloproliferative disorder
Liver Ultrasound with Doppler Studies normal right hepatic vein doppler study showing normal expected biphasic waveform across hepatic vein no hepatic vein, no venous flow
Characteristic Findings on Venography and CT • Caudate Hypertrophy and IVC Compression • Mottled parenchyma / lack of perfusion • Retroperitoneal Varices
A Brief Ascites Review • Don’t forget the total protein • >2.5: cardiac causes, Budd-Chiari • <2.5: portal hypertension/cirrhosis
Suggested by . . . • Hgb > 16.5 [F] or 18.5 [M] g/dL • Hct > 48 [F] or 52 [M] % • Increased RBC count, less useful The above are all concentrations/fractions and depend on the denominator – plasma volume GOLD = RBC Mass study; a dilution technique by self-transfusing radioactive tagged RBCs
Terms • Relative Polycythemia • Isolated decrease in plasma volume • aka Gaisböck’s syndrome, stress erythrocytosis • Absolute Polycythemia • Primary: PV and other rarer causes; low erythropoietin • Secondary: a circulating factor [epo] stimulates RBC production • Inappropriate secretion • Appropriate secretion
Polycythemias that are not PV • Inappropriate epo secretion: RCC/HCC • Appropriate epo secretion: think hypoxemia • Chronic pulmonary disease • Cyanotic heart disease • OSA, obesity/hypoventilation • High altitude • Chronic carbon monoxide exposure – smoking • Hemoglobinopathies that increase oxygen affinity • Miscellaneous: think cyclists • Anabolic steroids • Blood doping • Surreptitious use of ESA’s
Polycythemia Vera • A chronic myeloproliferative disorder like CML, ET, myelofibrosis • Untreated survival 6-18 months 2/2 thrombosis, malignant transformation • Treated survival > 10 years
Signs and Symptoms • HA, weakness, dizzy, diaphoretic, gout • Amaurosis, scotomata, ocular migraine • Pruritus: especially post bath/shower • Erythromelalgia: burning pain in feet and hands w/ accompanying pallor/cyanosis/erythema w/ present pulses microvascular thrombus • Arterial and venous thrombosis, often unusual • Splenomegaly, hepatomegaly, facial plethora
Other labs • Often PLT > 400k or WBC > 12k • Low epo level • Endogenous erythroid colony formation in vitro • BM Bx: hypercellular, iron absent • Presence of a JAK2 mutation
What is JAK2? A cytoplasmic tyrosine kinase critical for intracellular signaling from the receptors for erythropoeitin, thrombopoeitin, IL-3, GM-CSF
JAK2 and PV • >95% of all PV from JAK2 exon 14 mutation V617F [phenylalanine in place of valine] • The remainder can have exon 12 mutation • Leads to constitutively active JAK2 and dysregulated cellular signalling
Treatment • Phlebotomy to HCT < 42 [F] and 45 [M] % • Consider • Hydroxyurea • Low dose aspirin • IFN-alpha • Radioactive P32 • Allopurinol for gout
References • Campbell PJ, Green AR. “The myeloproliferative disorders”. N Engl J Med. 2006 Dec 7;355(23):2452-66. • Janssen H. L.A., Garcia-Pagan J.-C., Valla D.-C., Cardenas A., Menon K.V. N., Shah V., Kamath P. S. The Budd-Chiari Syndrome. N Engl J Med 2004; 350:1906-1908, Apr 29, 2004 • Up To Date Online